CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
48.84
4.67%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 46.66
Open 47.85
1-Year Change 29.92%
Day's Range 47.85 - 49.6
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 48.84 2.34 5.03% 46.50 50.06 46.50
Dec 19, 2024 46.66 0.28 0.60% 46.38 47.20 45.64
Dec 18, 2024 46.22 -1.62 -3.39% 47.84 49.20 45.94
Dec 17, 2024 47.70 -0.60 -1.24% 48.30 48.84 47.32
Dec 16, 2024 48.96 0.66 1.37% 48.30 49.47 48.30
Dec 13, 2024 48.61 -1.07 -2.15% 49.68 50.02 47.98
Dec 12, 2024 50.16 -0.04 -0.08% 50.20 50.46 49.48
Dec 11, 2024 50.63 0.30 0.60% 50.33 50.81 49.71
Dec 10, 2024 50.51 0.36 0.72% 50.15 51.03 50.09
Dec 9, 2024 50.41 -0.29 -0.57% 50.70 51.41 50.15
Dec 6, 2024 50.88 0.53 1.05% 50.35 51.89 50.11
Dec 5, 2024 50.35 0.64 1.29% 49.71 50.59 49.52
Dec 4, 2024 50.38 -0.71 -1.39% 51.09 51.43 50.26
Dec 3, 2024 51.39 1.11 2.21% 50.28 51.74 49.91
Dec 2, 2024 50.56 0.04 0.08% 50.52 51.47 50.22
Nov 29, 2024 51.80 -0.15 -0.29% 51.95 52.65 51.59
Nov 27, 2024 52.20 0.45 0.87% 51.75 52.76 51.47
Nov 26, 2024 51.94 2.36 4.76% 49.58 52.65 49.38
Nov 25, 2024 50.16 0.80 1.62% 49.36 50.99 49.30
Nov 22, 2024 49.01 1.50 3.16% 47.51 49.74 47.35

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cytokinetics Inc Company profile

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cytokinetics, Inc. revenues increased 26% to $70.4M. Net loss increased 69% to $215.3M. Revenues reflect License revenues increase of 50% to $54.9M, Milestone revenues increase of 79% to $5M. Higher net loss reflects Research and development increase of 66% to $149.5M (expense), Other General and administrative increase of 91% to $80.4M (expense).

Equity composition

Common Stock $.001 Par, 02/11, 170M auth., 66,910,100 o/s. Insiders and Straegic holds 9.82%. 4/29/04, 5,800,000 shares @ $13 per share by Goldman, Sachs & Co. 25/13, 1-for-6 Reverse Stock split.

Industry: Bio Therapeutic Drugs

350 Oyster Point Boulevard
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

BTC/USD

95,078.70 Price
-2.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

3,307.59 Price
-0.910% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.19 Price
-2.640% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01091

US100

21,392.60 Price
+0.620% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading